PI3K | GenomeWeb

PI3K

Using an algorithm known as HotNet2, an international team has identified more than a dozen genetically altered sub-networks in thousands of tumor samples assessed for the Cancer Genome Atlas project.

Early data presented at SABCS suggests that ER/PR-positive breast cancer patients could respond particularly well to Genentech's PI3 kinase inhibitor.

Researchers from the Dana Farber Cancer Institute have published results of a preliminary study tracking the patterns of mutations in the two histological subtypes of cervical cancer, which they are now planning to put to the test in a clinical trial of PI3 kinase inhibitors.

Sharing a co-exclusive license to PI3K with Qiagen, Roche will develop assays for diagnostic markers to help subsidiary Genentech and external pharma partners to advance investigational drug candidates that inhibit PI3K.

Roche announced this week that the co-exclusive license for the biomarker would allow it to develop real-time and endpoint PCR assays to detect mutations in the PI3K oncogene, which would aid its subsidiary Genentech in the development of several investigational drug candidates.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.